Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 337

1.

C6orf10 Low-Frequency and Rare Variants in Italian Multiple Sclerosis Patients.

Ziliotto N, Marchetti G, Scapoli C, Bovolenta M, Meneghetti S, Benazzo A, Lunghi B, Balestra D, Laino LA, Bozzini N, Guidi I, Salvi F, Straudi S, Gemmati D, Menegatti E, Zamboni P, Bernardi F.

Front Genet. 2019 Jun 26;10:573. doi: 10.3389/fgene.2019.00573. eCollection 2019.

2.

Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi.

Merli F, Cavallo F, Salvi F, Tucci A, Musuraca G, Nassi L, Merli M, Tani M, Gini G, Ferrari A, Molinari AL, Liberati AM, Conconi A, Matteucci P, Bari A, Scalone R, Ferrero S, Zanni M, Mammi C, Luminari S.

J Geriatr Oncol. 2019 Jul 8. pii: S1879-4068(18)30482-X. doi: 10.1016/j.jgo.2019.06.020. [Epub ahead of print]

PMID:
31296461
3.

Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL).

Salvi F, Luminari S, Tucci A, Massidda S, Liberati AM, Stelitano C, Zanni M, Re A, Centurioni R, Freilone R, Musuraca G, Nassi L, Patti C, Arcari A, Tani M, Pulsoni A, Pavone V, Volpetti S, Peli A, Evangelista A, Spina M, Ladetto M, Merli F.

Leuk Lymphoma. 2019 Jul 8:1-9. doi: 10.1080/10428194.2019.1608529. [Epub ahead of print]

PMID:
31282794
4.

Kinetic Investigation of a Presumed Nitronate Monooxygenase from Pseudomonas aeruginosa PAO1 Establishes a New Class of NAD(P)H:Quinone Reductases.

Reis RAG, Salvi F, Williams I, Gadda G.

Biochemistry. 2019 Jun 4;58(22):2594-2607. doi: 10.1021/acs.biochem.9b00207. Epub 2019 May 22.

PMID:
31075192
5.

Prevalence and Psychopathological Determinants of Sexual Dysfunction and Related Distress in Women With and Without Multiple Sclerosis.

Gava G, Visconti M, Salvi F, Bartolomei I, Seracchioli R, Meriggiola MC.

J Sex Med. 2019 Jun;16(6):833-842. doi: 10.1016/j.jsxm.2019.03.011. Epub 2019 Apr 19.

PMID:
31010780
6.

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).

Fabiani E, Calabrese C, Niscola P, Balleari E, Molteni A, Finelli C, Falconi G, Fenu S, Fianchi L, Criscuolo M, Salvi F, Lavorgna S, Buccisano F, Maurillo L, Lo Coco F, Cilloni D, Voso MT.

Br J Haematol. 2019 Jun;185(5):954-957. doi: 10.1111/bjh.15655. Epub 2018 Nov 8. No abstract available.

PMID:
30407614
7.

Effects of stably incorporated iron on protein phosphatase-1 structure and activity.

Salvi F, Trebacz M, Kokot T, Hoermann B, Rios P, Barabas O, Köhn M.

FEBS Lett. 2018 Dec;592(24):4028-4038. doi: 10.1002/1873-3468.13284. Epub 2018 Nov 23.

8.

Changes in expression profiles of internal jugular vein wall and plasma protein levels in multiple sclerosis.

Marchetti G, Ziliotto N, Meneghetti S, Baroni M, Lunghi B, Menegatti E, Pedriali M, Salvi F, Bartolomei I, Straudi S, Manfredini F, Voltan R, Basaglia N, Mascoli F, Zamboni P, Bernardi F.

Mol Med. 2018 Aug 9;24(1):42. doi: 10.1186/s10020-018-0043-4.

9.

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.

Messa E, Gioia D, Masiera E, Castiglione A, Ceccarelli M, Salvi F, Danise P, Sanna A, Allione B, Balleari E, Poloni A, Cametti G, Ferrero D, Tassara R, Finelli C, Bonferroni M, Musto P, Saglio G, Levis A, Santini V.

Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3. No abstract available.

10.

Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.

Gagliardi C, Perfetto F, Lorenzini M, Ferlini A, Salvi F, Milandri A, Quarta CC, Taborchi G, Bartolini S, Frusconi S, Martone R, Cinelli MM, Foffi S, Reggiani MLB, Fabbri G, Cataldo P, Cappelli F, Rapezzi C.

Eur J Heart Fail. 2018 Oct;20(10):1417-1425. doi: 10.1002/ejhf.1285. Epub 2018 Aug 2.

11.

Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.

Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D'Adda M, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W.

Blood. 2018 Aug 2;132(5):547-550. doi: 10.1182/blood-2018-03-835413. Epub 2018 Jun 13. No abstract available.

PMID:
29898955
12.

Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.

Salvi F, Volpe R, Pastorelli F, Bianchi A, Vella A, Rapezzi C, Mascalchi M.

J Stroke Cerebrovasc Dis. 2018 Sep;27(9):e212-e214. doi: 10.1016/j.jstrokecerebrovasdis.2018.04.033. Epub 2018 May 18.

PMID:
29779881
13.

Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.

Storti S, Spina M, Pesce EA, Salvi F, Merli M, Ruffini A, Cabras G, Chiappella A, Angelucci E, Fabbri A, Liberati AM, Tani M, Musuraca G, Molinari A, Petrilli MP, Palladino C, Ciancia R, Ferrario A, Gasbarrino C, Monaco F, Fraticelli V, De Vellis A, Merli F, Luminari S.

Haematologica. 2018 Aug;103(8):1345-1350. doi: 10.3324/haematol.2017.186569. Epub 2018 May 10.

14.

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.

Zaja F, Salvi F, Rossi M, Sabattini E, Evangelista A, Ciccone G, Angelucci E, Gaidano G, Zanni M, Ladetto M, Chiappella A, Vitolo U, Zinzani PL, Califano C, Tucci A, Patti C, Pileri SA, Lenti V, Piccaluga PP, Cavallo F, Volpetti S, Perali G, Assouline S, Mann KK, Morin R, Alcaide M, Bushell K, Fanin R, Levis A.

Leuk Lymphoma. 2018 Dec;59(12):2904-2910. doi: 10.1080/10428194.2018.1452208. Epub 2018 Apr 4.

PMID:
29616865
15.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

16.

Riluzole and other prognostic factors in ALS: a population-based registry study in Italy.

Mandrioli J, Malerba SA, Beghi E, Fini N, Fasano A, Zucchi E, De Pasqua S, Guidi C, Terlizzi E, Sette E, Ravasio A, Casmiro M, Salvi F, Liguori R, Zinno L, Handouk Y, Rizzi R, Borghi A, Rinaldi R, Medici D, Santangelo M, Granieri E, Mussuto V, Aiello M, Ferro S, Vinceti M; ERRALS Group.

J Neurol. 2018 Apr;265(4):817-827. doi: 10.1007/s00415-018-8778-y. Epub 2018 Feb 5.

PMID:
29404735
17.

Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC).

Frakulli R, Salvi F, Balestrini D, Palombarini M, Akshija I, Cammelli S, Morganti AG, Zompatori M, Frezza G.

Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S1-S7. doi: 10.21037/tlcr.2017.10.01.

18.

Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial.

Zamboni P, Tesio L, Galimberti S, Massacesi L, Salvi F, D'Alessandro R, Cenni P, Galeotti R, Papini D, D'Amico R, Simi S, Valsecchi MG, Filippini G; Brave Dreams Research Group.

JAMA Neurol. 2018 Jan 1;75(1):35-43. doi: 10.1001/jamaneurol.2017.3825.

19.

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.

Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M.

J Clin Oncol. 2018 Mar 1;36(7):689-696. doi: 10.1200/JCO.2017.74.1652. Epub 2017 Nov 2.

PMID:
29095677
20.

High Resolution M-mode Evaluation of Jugular Vein Valves in Patients with Neurological and Neurosensory Disorders.

Menegatti E, Tessari M, Vannini ME, Gianesini S, Malagoni AM, Ciorba A, Mazzoli M, Sisini F, Salvi F, Pelucchi S, Zamboni P.

Curr Neurovasc Res. 2017;14(4):316-322. doi: 10.2174/1567202614666171005122150.

PMID:
28982329
21.

Unusual case of spindle cell sarcoma metastases to right ventricle: a case report and a literature review.

Frakulli R, Cammelli S, Salvi F, Balestrini D, Baldissera A, Degli Esposti C, Martelli O, Abate M, Piaoli A, Ferrari S, Morganti AG, Frezza GP.

Ann Transl Med. 2017 Sep;5(17):344. doi: 10.21037/atm.2017.05.25.

22.

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.

Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F.

Am J Hematol. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29.

23.

Lower medulla hypoplasia in Friedreich ataxia: MR Imaging confirmation 140 years later.

Mascalchi M, Bianchi A, Ciulli S, Ginestroni A, Aiello M, Dotti MT, Salvi F, Nicolai E, Soricelli A, Diciotti S.

J Neurol. 2017 Jul;264(7):1526-1528. doi: 10.1007/s00415-017-8542-8. Epub 2017 Jun 15. No abstract available.

PMID:
28620720
24.

Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi.

Luminari S, Viel E, Ferreri AJM, Zaja F, Chimienti E, Musuraca G, Tucci A, Balzarotti M, Tani M, Salvi F, Pesce EA, Ferrari A, Liberati AM, Spadea A, Marino D, Bruno-Ventre M, Volpetti S, Bottelli C, Ravaioli E, Merli F, Spina M.

Hematol Oncol. 2018 Feb;36(1):68-75. doi: 10.1002/hon.2425. Epub 2017 May 19.

PMID:
28524259
25.

Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.

Messa E, Biale L, Castiglione A, Lunghi M, Bonferroni M, Salvi F, Allione B, Ferrero D, Calabrese C, De Gobbi M, Nicoli P, Gioia D, Levis A, Saglio G, Cilloni D.

Leuk Lymphoma. 2017 Nov;58(11):2752-2754. doi: 10.1080/10428194.2017.1312385. Epub 2017 May 9. No abstract available.

26.

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.

Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S.

Ann Oncol. 2017 Jul 1;28(7):1547-1553. doi: 10.1093/annonc/mdx154.

27.

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.

Zinzani PL, Pellegrini C, Chiappella A, Di Rocco A, Salvi F, Cabras MG, Argnani L, Stefoni V.

Blood. 2017 Apr 20;129(16):2328-2330. doi: 10.1182/blood-2017-01-764258. Epub 2017 Mar 6. No abstract available.

PMID:
28264798
28.

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.

Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3.

PMID:
28162984
29.

P037. Headache in multiple sclerosis: prevalence and clinical features in a case control-study.

Terlizzi R, Merli E, Buccellato E, Giannini G, Favoni V, Pierangeli G, Salvi F, Cortelli P, Cevoli S.

J Headache Pain. 2015 Dec;16(Suppl 1):A83. doi: 10.1186/1129-2377-16-S1-A83. No abstract available.

30.

Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study.

Zwarthoed C, El-Galaly TC, Canepari M, Ouvrier MJ, Viotti J, Ettaiche M, Viviani S, Rigacci L, Trentin L, Rusconi C, Luminari S, Cantonetti M, Bolis S, Borra A, Darcourt J, Salvi F, Subocz E, Tajer J, Kulikowski W, Malkowski B, Zaucha JM, Gallamini A.

J Nucl Med. 2017 Aug;58(8):1249-1254. doi: 10.2967/jnumed.116.184218. Epub 2017 Jan 26.

31.

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.

Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Montechiarello E, Ladetto M, Carmichael J, Fanin R.

Haematologica. 2017 May;102(5):e203-e206. doi: 10.3324/haematol.2016.154211. Epub 2017 Jan 12. No abstract available.

32.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U.

Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5.

PMID:
27927586
33.

Amyotrophic lateral sclerosis and myasthenia gravis: association or chance occurrence?

de Pasqua S, Cavallieri F, D'Angelo R, Salvi F, Fini N, D'Alessandro R, Rinaldi R, Fasano A, Mandrioli J.

Neurol Sci. 2017 Mar;38(3):441-444. doi: 10.1007/s10072-016-2787-3. Epub 2016 Dec 2.

PMID:
27913903
34.

Erratum to Diffuse Brain Hypoperfusion in Advanced Leukoencephalopathy with Calcifications and Cysts: Journal of Stroke and Cerebrovascular Diseases 2016:25(8 August):e111-e113.

Bartolini E, Bianchi A, Bartolomei I, Vella A, Sali L, Ciccarone A, Salvi F, Mascalchi M.

J Stroke Cerebrovasc Dis. 2017 Feb;26(2):457. doi: 10.1016/j.jstrokecerebrovasdis.2016.10.030. Epub 2016 Nov 2. No abstract available.

PMID:
27816278
35.

Synthesis of Highly Selective Submicromolar Microcystin-Based Inhibitors of Protein Phosphatase (PP)2A over PP1.

Fontanillo M, Zemskov I, Häfner M, Uhrig U, Salvi F, Simon B, Wittmann V, Köhn M.

Angew Chem Int Ed Engl. 2016 Nov 2;55(45):13985-13989. doi: 10.1002/anie.201606449. Epub 2016 Oct 10.

36.

Predictive validity of different versions of the Triage Risk Screening Tool.

Salvi F, Morichi V, Cherubini A.

Am J Emerg Med. 2016 Dec;34(12):2454-2456. doi: 10.1016/j.ajem.2016.09.029. Epub 2016 Sep 17. No abstract available.

PMID:
27769666
37.

Fixing the jugular flow reduces ventricle volume and improves brain perfusion.

Zamboni P, Menegatti E, Cittanti C, Sisini F, Gianesini S, Salvi F, Mascoli F.

J Vasc Surg Venous Lymphat Disord. 2016 Oct;4(4):434-45. doi: 10.1016/j.jvsv.2016.06.006.

PMID:
27638998
38.

Functional Annotation of a Presumed Nitronate Monoxygenase Reveals a New Class of NADH:Quinone Reductases.

Ball J, Salvi F, Gadda G.

J Biol Chem. 2016 Sep 30;291(40):21160-21170. Epub 2016 Aug 8.

39.

Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.

Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Salvi F, Merli F, Anastasia A, Luminari S, Annechini G, Gotti M, Peli A, Liberati AM, Di Renzo N, Castagna L, Giordano L, Carlo-Stella C.

J Clin Oncol. 2016 Sep 20;34(27):3293-9. doi: 10.1200/JCO.2016.66.4466. Epub 2016 Jul 5.

40.

Diffuse Brain Hypoperfusion in Advanced Leukoencephalopathy with Calcifications and Cysts.

Bartolini E, Bianchi A, Bartolomei I, Vella A, Sali L, Ciccarone A, Salvi F, Mascalchi M.

J Stroke Cerebrovasc Dis. 2016 Aug;25(8):e111-3. doi: 10.1016/j.jstrokecerebrovasdis.2016.04.030. Epub 2016 May 19. Erratum in: J Stroke Cerebrovasc Dis. 2017 Feb;26(2):457.

PMID:
27212271
41.

Is polypharmacy an independent risk factor for adverse outcomes after an emergency department visit?

Salvi F, Rossi L, Lattanzio F, Cherubini A.

Intern Emerg Med. 2017 Mar;12(2):213-220. doi: 10.1007/s11739-016-1451-5. Epub 2016 Apr 13.

PMID:
27075646
42.

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.

Pellegrini C, Dodero A, Chiappella A, Monaco F, Degl'Innocenti D, Salvi F, Vitolo U, Argnani L, Corradini P, Zinzani PL; Italian Lymphoma Foundation (Fondazione Italiana Linfomi Onlus, FIL).

J Hematol Oncol. 2016 Apr 12;9:38. doi: 10.1186/s13045-016-0266-1.

43.

Role of F357 as an Oxygen Gate in the Oxidative Half-Reaction of Choline Oxidase.

Salvi F, Rodriguez I, Hamelberg D, Gadda G.

Biochemistry. 2016 Mar 15;55(10):1473-84. doi: 10.1021/acs.biochem.5b01356. Epub 2016 Mar 3.

PMID:
26907558
44.

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A.

J Clin Oncol. 2016 Apr 20;34(12):1376-85. doi: 10.1200/JCO.2015.63.0699. Epub 2016 Feb 16.

45.

B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).

Balzarotti M, Brusamolino E, Angelucci E, Carella AM, Vitolo U, Russo E, Congiu A, Gotti M, Massidda S, Botto B, Annechini G, Spina M, Re A, Zilioli VR, Merli F, Salvi F, Stelitano C, Bonfichi M, Rodari M, Murru R, Magagnoli M, Anastasia A, Mazza R, Giordano L, Santoro A.

Leuk Lymphoma. 2016 Oct;57(10):2375-81. doi: 10.3109/10428194.2016.1140161. Epub 2016 Feb 15.

PMID:
26879066
46.

Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.

Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry.

Br J Haematol. 2016 Dec;175(5):975-979. doi: 10.1111/bjh.13902. Epub 2016 Jan 15. No abstract available.

PMID:
26773632
47.

Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).

Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A.

Br J Haematol. 2016 Mar;172(6):879-88. doi: 10.1111/bjh.13904. Epub 2016 Jan 13.

PMID:
26763986
48.

ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion.

Chiò A, Mora G, Sabatelli M, Caponnetto C, Lunetta C, Traynor BJ, Johnson JO, Nalls MA, Calvo A, Moglia C, Borghero G, Trojsi F, La Bella V, Volanti P, Simone I, Salvi F, Logullo FO, Riva N, Carrera P, Giannini F, Mandrioli J, Tanel R, Capasso M, Tremolizzo L, Battistini S, Murru MR, Origone P, Zollino M, Penco S; ITALSGEN consortium; SARDINIALS consortium, Mazzini L, D'Alfonso S, Restagno G, Brunetti M, Barberis M, Conforti FL.

Neurobiol Aging. 2016 Mar;39:218.e5-8. doi: 10.1016/j.neurobiolaging.2015.11.027. Epub 2015 Dec 8.

49.

Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT.

Lopci E, Grassi I, Rubello D, Colletti PM, Cambioli S, Gamboni A, Salvi F, Cicoria G, Lodi F, Dazzi C, Mattioli S, Fanti S.

Clin Nucl Med. 2016 Feb;41(2):e87-92. doi: 10.1097/RLU.0000000000001017.

PMID:
26447388
50.

Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas.

Frakulli R, Salvi F, Balestrini D, Parisi A, Palombarini M, Cammelli S, Rocca M, Salone M, Longhi A, Ferrari S, Morganti AG, Frezza G.

Anticancer Res. 2015 Oct;35(10):5581-6.

PMID:
26408729

Supplemental Content

Support Center